OS THERAPIES INC (OSTX) Stock News

USA - NYSEARCA:OSTX - US68764Y2072 - Common Stock

1.89 USD

-0.05 (-2.58%)

Last: 11/11/2025, 8:04:00 PM

1.88 USD

-0.01 (-0.53%)

After Hours: 11/11/2025, 8:04:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OSTX Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga

OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate

3 months ago - By: Benzinga

Earnings Outlook For OS Therapies

3 months ago - By: The Motley Fool

Os Therapies Posts Wider Loss in Q2

4 months ago - By: OS Therapies

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

5 months ago - By: OS Therapies

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

5 months ago - By: OS Therapies

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

5 months ago - By: OS Therapies Inc.

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

5 months ago - By: OS Therapies Inc.

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

6 months ago - By: OS Therapies Inc.

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: OS Therapies

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

6 months ago - By: OS Therapies

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

6 months ago - By: OS Therapies

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

7 months ago - By: OS Therapies

OS Therapies FDA Meeting Request Granted

7 months ago - By: OS Therapies

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans